DK0607156T3 - Fremgangsmåde til fremstilling af konserverede lægemidler indeholdende humane proteiner til infusions- eller injektionsformål - Google Patents

Fremgangsmåde til fremstilling af konserverede lægemidler indeholdende humane proteiner til infusions- eller injektionsformål

Info

Publication number: DK0607156T3
Authority: DK; Denmark
Prior art keywords: preservative; prepn; infusion; human protein; sodium
Prior art date: 1991-08-15

Application number

DK92916938.1T

Other languages

Danish (da)

English (en)

Inventor

Heinrich Woog

Werner Gruber

Hans-J Markl

Gerhard Winter

Fritz Demmer

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-15

Filing date

1992-08-10

Publication date

1997-04-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6438353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0607156(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-08-10 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1997-04-07 Application granted granted Critical

1997-04-07 Publication of DK0607156T3 publication Critical patent/DK0607156T3/da

Links

102000003839 Human Proteins Human genes 0.000 title abstract 4
108090000144 Human Proteins Proteins 0.000 title abstract 4
238000001802 infusion Methods 0.000 title abstract 2
238000002347 injection Methods 0.000 title abstract 2
239000007924 injection Substances 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000003755 preservative agent Substances 0.000 abstract 5
230000002335 preservative effect Effects 0.000 abstract 5
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 abstract 3
229960004926 chlorobutanol Drugs 0.000 abstract 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 abstract 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
229960000686 benzalkonium chloride Drugs 0.000 abstract 1
229960004217 benzyl alcohol Drugs 0.000 abstract 1
235000019445 benzyl alcohol Nutrition 0.000 abstract 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
239000012928 buffer substance Substances 0.000 abstract 1
ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000001630 malic acid Substances 0.000 abstract 1
235000011090 malic acid Nutrition 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229940070805 p-chloro-m-cresol Drugs 0.000 abstract 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
229910000160 potassium phosphate Inorganic materials 0.000 abstract 1
235000011009 potassium phosphates Nutrition 0.000 abstract 1
159000000001 potassium salts Chemical class 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000009257 reactivity Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000011734 sodium Chemical class 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
239000001509 sodium citrate Substances 0.000 abstract 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
239000001488 sodium phosphate Substances 0.000 abstract 1
229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
238000004448 titration Methods 0.000 abstract 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

DK92916938.1T 1991-08-15 1992-08-10 Fremgangsmåde til fremstilling af konserverede lægemidler indeholdende humane proteiner til infusions- eller injektionsformål DK0607156T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4126983A DE4126983A1 (de)	1991-08-15	1991-08-15	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke

Publications (1)

Publication Number	Publication Date
DK0607156T3 true DK0607156T3 (da)	1997-04-07

Family

ID=6438353

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92916938.1T DK0607156T3 (da)	1991-08-15	1992-08-10	Fremgangsmåde til fremstilling af konserverede lægemidler indeholdende humane proteiner til infusions- eller injektionsformål

Country Status (25)

Country	Link
US (2)	US5503827A (cs)
EP (2)	EP0528313A1 (cs)
JP (1)	JP3670660B2 (cs)
KR (1)	KR100263282B1 (cs)
AT (1)	ATE145138T1 (cs)
AU (2)	AU678756B2 (cs)
CA (1)	CA2115348C (cs)
CZ (1)	CZ284853B6 (cs)
DE (2)	DE4126983A1 (cs)
DK (1)	DK0607156T3 (cs)
ES (1)	ES2094923T3 (cs)
FI (1)	FI112169B (cs)
GE (1)	GEP19981289B (cs)
GR (1)	GR3022037T3 (cs)
HU (1)	HU227421B1 (cs)
IL (1)	IL102775A (cs)
MX (1)	MX9204636A (cs)
NO (1)	NO309844B1 (cs)
RU (1)	RU2091068C1 (cs)
SG (1)	SG66226A1 (cs)
SK (1)	SK281910B6 (cs)
TW (1)	TW351677B (cs)
UA (1)	UA26343C2 (cs)
WO (1)	WO1993003744A1 (cs)
ZA (1)	ZA926122B (cs)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3939346A1 (de) *	1989-11-29	1991-06-06	Behringwerke Ag	Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242863A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
SE9300105D0 (sv) *	1993-01-15	1993-01-15	Kabi Pharmacia Ab	Stable protein solution
US5482931A (en) *	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions
JP3541054B2 (ja) *	1994-04-21	2004-07-07	ユニ・チャーム株式会社	使い捨ておむつ
US5766582A (en) *	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US5888968A (en) *	1995-06-07	1999-03-30	Chiron Corporation	TFPI formulation
EP0837883B1 (en) *	1995-06-07	2005-08-10	Chiron Corporation	Method of solubilizing, purifying, and refolding protein
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
AU1750997A (en) *	1996-01-19	1997-08-11	Eli Lilly And Company	Obesity protein formulations
WO1997026011A1 (en) *	1996-01-19	1997-07-24	Eli Lilly And Company	Obesity protein formulations
TW518219B (en)	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
US20030190307A1 (en) *	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6410511B2 (en) *	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
DE19716154A1 (de) *	1997-04-18	1998-10-22	Boehringer Mannheim Gmbh	Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
DK0917879T3 (da) *	1997-11-22	2002-11-04	Roche Diagnostics Gmbh	Forbedret fremgangsmåde til stabilisering af proteiner
JP2001525341A (ja) *	1997-11-28	2001-12-11	ロッシュディアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	活性ヘッジホッグタンパク質変異体、その調製方法及び医薬への適用
JP3723857B2 (ja) *	1998-02-04	2005-12-07	日本ケミカルリサーチ株式会社	ヒト成長ホルモン含有水性医薬組成物
US6776983B1 (en)	1998-03-06	2004-08-17	Chugai Seiyaku Kabushiki Kaisha	Protein free formulations
US20050203187A1 (en) *	1998-06-01	2005-09-15	Verbiscar Anthony J.	Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
RU2234942C2 (ru) *	1998-07-14	2004-08-27	Корикса Корпорейшн	Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6207718B1 (en)	1998-08-07	2001-03-27	Ontogeny, Inc.	Pharmaceutical compositions containing hedgehog protein
US6979442B1 (en) *	1998-08-17	2005-12-27	Pfizer Inc.	Stabilized protein compositions
ATE401908T1 (de) *	1999-04-09	2008-08-15	Ortho Mcneil Pharm Inc	Pharmazeutische zusammensetzungen von erythropoietin
BR0012674A (pt)	1999-07-22	2002-09-17	Aventis Pharma Inc	Formulações farmacêuticas preservadas
CZ302750B6 (cs) *	1999-07-22	2011-10-19	Aventis Holdings Inc.	Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
TR200401573T4 (tr)	2000-02-29	2004-08-23	Pfizer Products Inc.	Stabilize edilmiş granülosit koloni uyarıcı faktör
US20020141970A1 (en) *	2001-03-05	2002-10-03	Pettit Dean K.	Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6818613B2 (en) *	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
RU2218151C2 (ru) *	2001-12-11	2003-12-10	Замаев Ильяс Амсудинович	Способ консервации растворов лекарственных средств
ES2615484T3 (es) *	2002-05-21	2017-06-07	Daiichi Sankyo Company, Limited	Composiciones medicinales que contienen grelina
SI21257A (sl) *	2002-07-17	2004-02-29	LEK farmacevtska dru�ba d.d.	Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
WO2004084859A2 (en) *	2003-03-21	2004-10-07	Nastech Pharmaceutical Company Inc.	Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) *	2003-04-02	2003-04-17	Norika Holdings	Sterilisation process for pharmaceutical product
ATE553747T1 (de) *	2003-06-10	2012-05-15	Lg Life Sciences Ltd	Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
DE10333317A1 (de) *	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7851433B2 (en) *	2003-08-13	2010-12-14	Novartis Vaccines And Diagnostics, Inc.	Method of purifying TFPI and TFPI analogs
EP1532983A1 (en) *	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
DE202005005094U1 (de) *	2005-03-31	2005-07-28	Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh	Ophthalmische Zusammensetzung
AU2006295340B2 (en) *	2005-08-05	2010-11-11	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE202006020194U1 (de)	2006-03-01	2007-12-06	Bioceuticals Arzneimittel Ag	G-CSF-Flüssigformulierung
DK2197919T3 (da) *	2007-08-27	2014-07-07	Ratiopharm Gmbh	Flydende formulering af g-csf-konjugat
PT2076243E (pt)	2007-08-27	2014-12-05	Ratiopharm Gmbh	Formulação líquida de g-csf
EP3381445B1 (en)	2007-11-15	2023-10-25	Amgen Inc.	Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2412385A1 (en) *	2008-02-08	2012-02-01	BioGeneriX AG	Liquid formulation of FSH
US8120369B2 (en)	2009-03-02	2012-02-21	Harris Corporation	Dielectric characterization of bituminous froth
JP6125141B2 (ja)	2009-09-25	2017-05-10	株式会社アールテック・ウエノ	点眼剤
JP6078344B2 (ja)	2010-02-04	2017-02-08	ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト	免疫グロブリン製剤
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
HUE052280T2 (hu)	2014-12-03	2021-04-28	Csl Behring Ag	Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
WO2018187590A1 (en) *	2017-04-05	2018-10-11	Modernatx, Inc.	Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
AU2019242912B2 (en)	2018-03-28	2025-07-17	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in DNA isolated from exosomes
US20210024936A1 (en) *	2018-04-09	2021-01-28	Board Of Regents, The University Of Texas System	Therapeutic targeting of oncogenes using exosomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3106073A1 (de) *	1981-02-19	1982-08-19	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
GB2177914B (en) *	1985-06-04	1989-10-25	Chugai Pharmaceutical Co Ltd	A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
AU648509B2 (en) *	1989-07-14	1994-04-28	Wyeth Holdings Corporation	Stable vaccine compositions containing interleukins
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en)	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions

1991
- 1991-08-15 DE DE4126983A patent/DE4126983A1/de not_active Withdrawn
1992
- 1992-08-05 TW TW081106209A patent/TW351677B/zh not_active IP Right Cessation
- 1992-08-10 RU RU9294016163A patent/RU2091068C1/ru active
- 1992-08-10 AT AT92916938T patent/ATE145138T1/de active
- 1992-08-10 ES ES92916938T patent/ES2094923T3/es not_active Expired - Lifetime
- 1992-08-10 EP EP92113571A patent/EP0528313A1/de active Pending
- 1992-08-10 AU AU24094/92A patent/AU678756B2/en not_active Expired
- 1992-08-10 US US08/193,002 patent/US5503827A/en not_active Expired - Lifetime
- 1992-08-10 CA CA002115348A patent/CA2115348C/en not_active Expired - Lifetime
- 1992-08-10 SK SK148-94A patent/SK281910B6/sk not_active IP Right Cessation
- 1992-08-10 HU HU9400416A patent/HU227421B1/hu unknown
- 1992-08-10 WO PCT/EP1992/001822 patent/WO1993003744A1/de not_active Ceased
- 1992-08-10 IL IL10277592A patent/IL102775A/en not_active IP Right Cessation
- 1992-08-10 DK DK92916938.1T patent/DK0607156T3/da active
- 1992-08-10 SG SG1996001887A patent/SG66226A1/en unknown
- 1992-08-10 UA UA94005433A patent/UA26343C2/uk unknown
- 1992-08-10 KR KR1019940700453A patent/KR100263282B1/ko not_active Expired - Lifetime
- 1992-08-10 JP JP50407293A patent/JP3670660B2/ja not_active Expired - Lifetime
- 1992-08-10 EP EP92916938A patent/EP0607156B1/de not_active Expired - Lifetime
- 1992-08-10 CZ CZ94287A patent/CZ284853B6/cs not_active IP Right Cessation
- 1992-08-10 DE DE59207523T patent/DE59207523C5/de not_active Expired - Lifetime
- 1992-08-11 MX MX9204636A patent/MX9204636A/es unknown
- 1992-08-14 ZA ZA926122A patent/ZA926122B/xx unknown
- 1992-10-15 GE GEAP19923057A patent/GEP19981289B/en unknown
1994
- 1994-02-14 NO NO940499A patent/NO309844B1/no not_active IP Right Cessation
- 1994-02-14 FI FI940674A patent/FI112169B/fi not_active IP Right Cessation
1996
- 1996-01-30 US US08/593,579 patent/US6303113B1/en not_active Expired - Fee Related
- 1996-12-13 GR GR960403464T patent/GR3022037T3/el unknown
1997
- 1997-03-17 AU AU16339/97A patent/AU710768B2/en not_active Expired

Also Published As

Publication number	Publication date
NO940499L (no)	1994-02-14
AU710768B2 (en)	1999-09-30
CZ284853B6 (cs)	1999-03-17
SK281910B6 (sk)	2001-09-11
NO309844B1 (no)	2001-04-09
KR100263282B1 (ko)	2000-08-01
IL102775A0 (en)	1993-01-31
UA26343C2 (uk)	1999-08-30
AU678756B2 (en)	1997-06-12
HU227421B1 (en)	2011-05-30
EP0607156A1 (de)	1994-07-27
FI940674L (fi)	1994-02-14
CZ28794A3 (en)	1994-08-17
RU94016163A (ru)	1996-08-10
AU1633997A (en)	1997-05-22
JP3670660B2 (ja)	2005-07-13
IL102775A (en)	1999-12-22
CA2115348C (en)	2007-07-17
ZA926122B (en)	1994-02-14
HU9400416D0 (en)	1994-05-30
GR3022037T3 (en)	1997-03-31
TW351677B (en)	1999-02-01
EP0607156B1 (de)	1996-11-13
SG66226A1 (en)	1999-07-20
SK14894A3 (en)	1994-11-09
FI112169B (fi)	2003-11-14
DE4126983A1 (de)	1993-02-18
HUT67379A (en)	1995-04-28
DE59207523C5 (de)	2006-11-16
DE59207523D1 (de)	1996-12-19
WO1993003744A1 (de)	1993-03-04
ATE145138T1 (de)	1996-11-15
CA2115348A1 (en)	1993-03-04
NO940499D0 (no)	1994-02-14
AU2409492A (en)	1993-03-16
FI940674A0 (fi)	1994-02-14
EP0528313A1 (de)	1993-02-24
JPH06510031A (ja)	1994-11-10
US5503827A (en)	1996-04-02
RU2091068C1 (ru)	1997-09-27
MX9204636A (es)	1993-02-01
US6303113B1 (en)	2001-10-16
ES2094923T3 (es)	1997-02-01
GEP19981289B (en)	1998-05-01

Publication	Publication Date	Title
FI940674A0 (fi)	1994-02-14	Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi
LV10178A (lv)	1994-10-20	Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
DE69329367D1 (de)	2000-10-12	Wachstumshormon-enthaltendeproteinformulierung
ES445542A1 (es)	1977-06-01	Procedimiento de obtencion de laminas de recubrimiento para aplicaciones cosmeticas.
DE69531314D1 (de)	2003-08-21	Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
NO893882D0 (no)	1989-09-29	Middel til forbedring av lipidmetabolisme og fremgangsmaate ved anvendelse derav.
IE38514L (en)	1974-05-16	Insulin preparations.
DE69513635D1 (de)	2000-01-05	Wässrige zubereitung mit verzögerter wirkstofffreigabe
FR2185416A1 (en)	1974-01-04	Isotonic injectable ACTH compsns - with low content of polyphloretin phosphate, but with prolonged activity
ATE190837T1 (de)	2000-04-15	Aminosäureergänzung
IT1247752B (it)	1994-12-30	Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
JPS56115722A (en)	1981-09-11	Analgesic